Nasdaq Btai News Today : Breaking News, Live Updates & Top Stories | Vimarsana

BioXcel Therapeutics (NASDAQ:BTAI – Get Free Report) and Kazia Therapeutics (NASDAQ:KZIA – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, earnings, profitability and analyst recommendations. Volatility and Risk BioXcel Therapeutics has a […]

BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Free Report) CEO Vimal Mehta sold 5,268 shares of the firm’s stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $2.62, for a total transaction of $13,802.16. Following the sale, the chief executive officer now owns 43,564 shares of the company’s […]

UBS Group restated their neutral rating on shares of BioXcel Therapeutics (NASDAQ:BTAI – Free Report) in a research note issued to investors on Wednesday morning, MarketBeat reports. They currently have a $4.00 target price on the stock, down from their previous target price of $9.00. Separately, HC Wainwright reissued a buy rating and set a […]

Shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Free Report) have been given an average recommendation of “Hold” by the six ratings firms that are currently covering the company, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average […]

Shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Free Report) have earned an average recommendation of “Hold” from the seven analysts that are presently covering the company, MarketBeat Ratings reports. Five research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 12-month price […]